Treatment end-points, depending on surrogate markers alone, in particular hepatitis B e-antigen seroconversion, may not be ideal for patients who acquire the disease early in life. Currently ...

but for seroconversion rates, the groups were judged to be equivalent. For hepatitis B, no significant differences were noted. The accelerated schedule was well tolerated by all subjects ...

Hepatitis B, spread through bodily fluids ... oral NA therapy daily until meeting the criteria for stopping. HBsAg ...

Less often, treatment can lead to loss of hepatitis B antigens and promote production of antibodies (known as seroclearance and seroconversion). The most effective antiviral drugs usually produce low ...

Stage 3 – inactive carriage: During this stage, the body produces antibodies against hepatitis B, a process known as seroconversion. During this inactive stage, the immune system controls the virus so ...